FibroGen Investor Suit Dismissed Following $28.5 Million Deal

FibroGen Inc. is free of investor allegations tied to an anti-anemia drug following the distribution of a $28.5 million settlement.

Judge Edward M. Chen dismissed the claims with prejudice, asking the clerk to enter final judgment in his order entered Tuesday. The US District Court for the Northern District of California judge approved sending the remaining net settlement balance of almost $22,000 plus an anticipated tax refund of nearly $39,000 to court-approved recipient the Public Justice Foundation.

• Investors alleged FibroGen and top executives misrepresented the safety and efficacy data of its drug candidate Roxadustat, which targets anemia associated with chronic ...